Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
50 results about "Multikinase inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Multikinase inhibitors work by inhibiting multiple intracellular and cell surface kinases, some of which are implicated in tumor growth and metastatic progression of cancer, thus decreasing tumor growth and replication. Multikinase inhibitors may be used to treat advanced kidney cancer as well as other specific types of cancer.
Combination therapy using active immunotherapy
InactiveUS20090004213A1Organic active ingredientsCancer antigen ingredientsSunitinib malateMajor histocompatibility
The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and / or sorafenib tosylate or a pharmaceutically acceptable salt thereof.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Azaindole derivatives as multi kinase inhibitors
Owner:ORIBASE PHARMA
Methods for treating thyroid cancer
The invention provides methods for enhancing iodine absorption in a thyroid in a subject and treating thyroid cancer by administering to the subject a composition which includes a multi-kinase inhibitor. Furthermore, the invention provides methods for improving a medical diagnostic procedure based on radioactive iodine in a subject by administering to the subject a composition comprising a multi-kinase inhibitor.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Multikinase Inhibitors for Use in the Treatment of Cancer
Owner:EISIA R&D MANAGEMENT CO LTD +1
Compositions and methods for treating pterygium
ActiveUS9980901B2Stabilization of pterygium sizeStabilizing pterygiumOrganic active ingredientsSenses disorderPurine AntimetaboliteSurgery
Compositions and methods for inducing pterygium regression from visual axis / central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.
Owner:CLOUDBREAK THERAPEUTICS LLC
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
Owner:BAYER HEALTHCARE LLC
Biomarkers for inhibitors with anti-angiogenic activity
The invention relates to a method for assessing the effect of integrin inhibitors and small molecule ATP site directed multi kinase inhibitors on angiogenesis by the use of certain identified biomarkers. This method is notably beneficial for the determination of the efficacy of integrin inhibitors and small molecule ATP site directed multi-kinase inhibitors mainly used for the treatment of angiogenesis associated diseases such as cancer. Especially, the invention relates to biomarkers linked to angiogenesis that are preferably accessible in body fluids and therefore allow analysis of target modulation in a non-invasive way. The use of said biomarkers for the screening of compounds with integrin-inhibitory activity is also disclosed.
Owner:MERCK PATENT GMBH
Compositions and methods for treating pterygium
Owner:BOYUN BIOMEDICAL TECH GUANGZHOU CO LTD
Oral delivery system for sorafenib tosylate
The present invention relates to a gastroretentive tablet for treating unresectable hepatocellular carcinoma, comprising an enteric polymer, a nanoparticle and an excipient, wherein the nanoparticle comprises an oral multikinase inhibitor, wherein the oral multikinase inhibitor is coated with an amino methacrylate copolymer, wherein the oral multikinase inhibitor is sorafenib, and wherein the enteric polymer is methacrylic acid copolymer. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof.
Owner:WONG DAVID
Azaindole derivatives as multi kinase inhibitors
The present invention relates to compounds of the following formula (I) and / or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.
Owner:ORIBASE PHARMA
Multikinase inhibitor
InactiveUS20100168430A1Excellent in in vivo dynamic and in safetyEnhanced inhibitory effectSenses disorderOrganic chemistryHydrogen atomBinding site
It is intended to provide a compound represented by the formula (1):[wherein Ar is an arylene group to be attached selected from the following formula (2):(wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents —(O)n—R; R represents a C1-C6 alkyl group or the like; n represents 0 or 1; X represents O or the like; R2, R3 and R4 are independently selected from a hydrogen atom or C1-C3 alkyl; or R2 and R3 may join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.
Owner:CHUGAI PHARMA CO LTD +1
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
Owner:BAYER HEALTHCARE LLC
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
Gene expression signature predictive of cancer patient response to multi-kinase inhibitor is disclosed. Also disclosed are methods predicting the efficacy of the multi-kinase inhibitor for treating cancer in a patient. Also disclosed are methods for distinguishing responders from non-responders to a multi-kinase inhibitor in treating cancer. Also disclosed are methods for treating a cancer patient with a multi-kinase inhibitor.
Owner:CROWN BIOSCI INC TAICANG
LED Treatment of Dermatologic Toxicities Associated with Multikinase Inhibitors
InactiveUS20110196351A1Treating preventing toxicityAvoid managementSurgical instrument detailsLight therapyLight-emitting diodeMultikinase inhibitor
The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and / or nails, which are associated with administration of one or more multikinase inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.
Owner:DELAND M MAITLAND +1
Multi-kinase inhibitor compound, and crystal form and use thereof
ActiveUS10208042B1Improve pharmacological activityMaintain good propertiesOrganic active ingredientsOrganic chemistry methodsMorpholineX-ray
The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e] [1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.
Owner:TRANSTHERA SCIENCES (NANJING) INC
LED treatment of dermatologic toxicities associated with multikinase inhibitors
InactiveUS8795263B2Treating preventing toxicityAvoid managementSurgical instrument detailsLight therapyDermatologyLight-emitting diode
The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and / or nails, which are associated with administration of one or more multikinase inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.
Owner:DELAND M MAITLAND +1
A topical composition for treating rosacea and a method for treating rosacea with the same
ActiveUS20200121675A1Reduces abnormal neurovascular regulationOintment deliveryDermatological disorderVascular Endothelial Growth Factor ReceptorPharmacology
A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.
Owner:ADS THERAPEUTICS LLC
Carbamate and urea compounds as multikinase inhibitors
The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors andmethods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.
Owner:ANGEX PHARMA INC
5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
InactiveCN113321645AImprove or prevent diseaseImprove or prevent proliferationOrganic chemistryImmunological disordersDiseasePerylene derivatives
Owner:ANRUI PHARMA CO LTD
Deuterated rigosertib
ActiveUS9249093B2Reduce severitySuppress and attenuate and diminish and arrestBiocideSulfur/selenium/tellurium active ingredientsDiseasePhosphatidylinositol 3-Kinases
This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
Owner:SUN PHARMA IND INC
Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
A multi-kinase inhibitor, in particular Sorafenib, is used for the preparation of a pharmaceutical composition in the treatment of a variety of pathological conditions involving vascular hyperpermeability in order to reduce vascular hyperpermeability.
Owner:IST NAZ PER LO STUDIO E LA CURA DEI TUMORI
Methods for preventing or treating cancer resistance to EGFR inhibition
InactiveUS20200237736A1Avoid problemsInhibiting cancer resistanceAntibody ingredientsAntineoplastic agentsCancer cellOncology
The invention relates to methods for preventing or treating resistance to EGFR inhibitors in cancer patients. More particularly, after performing a screen for small molecules potentially capable of countering cancer resistance to EGFR TKI, inventors identified the multikinase inhibitor sorafenib, which has the property, in combination with EGFR TKI, to prevent the enrichment of tumor cells containing mutations responsible for NSCLC resistance to first and third generation EGFR TKI. These data indicate that this multikinase inhibitor can prevent resistance to several generations of EGFR TKI. These in vitro data were confirmed in an in vivo xenograft mouse model of NSCLC. Finally these data were reproduced in cancer cells using SC-1, a sorafenib analogue. Accordingly, the invention relates to a method of preventing and / or treating cancer resistance to treatment with an epidermal growth factor receptor (EGFR) inhibitor in a subject in need thereof comprising administering to the subject sorafenib drug or sorafenib analogue, alone or in combination with an EGFR inhibitor.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Fused pyrimidine compounds and use thereof
InactiveUS20160068513A1Organic active ingredientsGroup 5/15 element organic compoundsPharmaceutical drugPharmaceutical medicine
Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
Owner:MEDIVATION TECH INC
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
Gene expression signature predictive of cancer patient response to multi-kinase inhibitor is disclosed. Also disclosed are methods predicting the efficacy of the multi-kinase inhibitor for treating cancer in a patient. Also disclosed are methods for distinguishing responders from non-responders to a multi-kinase inhibitor in treating cancer. Also disclosed are methods for treating a cancer patient with a multi-kinase inhibitor.
Owner:CROWN BIOSCI INC TAICANG
Multikinase inhibitors of VEGF and tfg beta and uses thereof
A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.
Owner:AIVIVA BIOPHARMA INC
Multikinase inhibitors and uses in ocular fibrosis
A method for preventing and / or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis / scarring, retinal gliosis, or formation of choroidal membranes.
Owner:AIVIVA BIOPHARMA INC
Multi-kinase inhibitor compound, and crystal form and use thereof
ActiveUS20190040064A1Improve pharmacological activityMaintain good propertiesOrganic active ingredientsOrganic chemistry methodsMorpholineX-ray
The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.20, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.
Owner:TRANSTHERA SCIENCES (NANJING) INC
Multikinase inhibitors and uses in prostatic hyperplasia and urinary track diseases
ActiveUS11376252B2Treating/preventing benign prostate hyperplasiaLow urinary tract symptomPharmaceutical delivery mechanismUrinary disorderDiseaseRegorafenib
A method for preventing, treating and / or improving a prostatic disease or disorder associated with epithelial hyperplasia and / or fibrosis, comprising: administering an effective amount of a multikinase inhibitor to a subject in need thereof, wherein the multikinase inhibitor has a certain spectrum of kinase inhibitory activity. The multikinase inhibitor is sunitinib, regorafenib, ponatinib, pazopanib, nintedanib and / or lenvatinib. The prostatic disease or disorder is selected from the group consisting of benign prostate hyperplasia and its associated lower urinary tract symptoms, fibrosis of ureters and renal pelvis, prostate adenoma, and prostatic intraepithelial neoplasia in animals and humans.
Owner:AIVIVA BIOPHARMA INC
Combination therapy for the treatment of pancreatic cancer
The subject matter described herein is directed to compositions comprising a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor that targets PDGFRα, S6 and STAT3 or a pharmaceutically acceptable salt thereof, and their use in treating pancreatic cancer. In another aspect, disclosed herein are methods of treating pancreatic cancer by administering a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor, or a pharmaceutically acceptable salt thereof. In another aspect, the combination of cobimetinib, or a pharmaceutically acceptable salt thereof, and ponatinib or a pharmaceutically acceptable salt thereof is administered in a composition or the combination is administered separately to treat pancreatic cancer.
Owner:GENENTECH INC
Pharmaceutical preparation composition of pyrrolopyrimidine derivatives as alk/fak/igf1r multi-kinase inhibitors and preparation method thereof
ActiveCN108653218BReduce degradation reactionGood dispersionOrganic active ingredientsOrganic chemistryHypromellose DerivativesPharmaceutical drug
Owner:SHOUYAO HLDG BEIJING CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com